Domain Therapeutics - A unique GPCR company in Immuno-Oncology
Our mission is to lead the clinical development of innovative therapeutics that will be game-changers for cancer patients. We are fully dedicated to unlocking the power of immune system. Our goal is to bring innovative therapeutics that can rearm the immune system and help achieve the best possible outcome for cancer patients. We are developing a unique pipeline of first-in-class and best-in-class treatments to reverse GPCR-mediated immunosuppression and resistance to immune checkpoint inhibitors. We develop innovative treatments that target GPCR mediated immunosuppression. We are steadfast in our commitment to precision research, striving to deliver differentiated and highly effective GPCR-targeting cancer immunotherapies that offer maximum benefit to patients. Our goal is to reverse GPCR-mediated immunosuppression in immuno-oncology. Domain Therapeutics is a global clinical-stage biopharmaceutical company, pioneering the unique and visionary approach of GPCR-targeting cancer immunotherapies.
Verified
Domain presents the last generation of bioSens-All™ platform dedicated to checkpoint inhibitors at the AACR 2020 - Domain Therapeutics Group
Check out our virtual posters ! Available on our website and at the #AACR20 from June 22, 2020 at 9:00 AM EDT. Development of a pharmacological platform to study in real time immune checkpoints signaling pathways: validation with therapeutics mAbs and small molecules (Poster #6308) presents the last generation of bioSens-All™ platform dedicated to the identification and […]
Verified
Domain Therapeutics and Merck enter into a license and collaboration agreement for development of adenosine receptor antagonists in immuno-oncology - Domain Therapeutics Group
Merck to develop Domain Therapeutics’ next generation adenosine receptor programs for use in combination with immune checkpoint inhibitors Strasbourg, France, January 23, 2017 – Domain Therapeutics today announces that a collaboration and licensing agreement with Merck, a leading science and technology company, has been signed for the development of adenosine receptor antagonist drugs specifically […]
Verified
Platforms - Domain Therapeutics Group
A unique platform for our drug discovery in immuno-oncology Target Identification platform Over years, we have built up a pipeline of assets in immuno-oncology to tackle GPCR-mediated immunosuppression. To fuel this pipeline, we have structured a polyvalent and unique platform based on the identification and the cross-validation of GPCRs involved in immunosuppression mechanisms. Such platform […]
View all products
Keywords
Industries
CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10m in the fifth call for hospital-university research in health (RHU) projects - Domain Therapeutics Group
January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than […]
Where is Domain Therapeutics located?
The company Domain Therapeutics is located in Illkirch-Graffenstaden, Grand Est, France. It's worth noting that the company may has more corporate locations
How many employees does Domain Therapeutics approximately have?
As of the latest available information Domain Therapeutics has around 11-50 employees worldwide.
When was Domain Therapeutics founded?
Domain Therapeutics was founded in 2001
In which industries does Domain Therapeutics mainly work?
The company Domain Therapeutics has it's main focus in the industries of Biotechnology, Science and Engineering, Health Care
Exinda Therapeutics, LLC
United States
1-10 Employees
2013
Teon Therapeutics
United States
11-50 Employees
2017
Teclison Limited
United States
1-10 Employees
2015
Agenus
United States
251-500 Employees
1994
Immune-Onc Therapeutics
United States
11-50 Employees
2016
Morphogenesis
United States
11-50 Employees
1995
Cue Biopharma
United States
11-50 Employees
2014
Scopus BioPharma
United States
1-10 Employees
2018
Topics which have been searched by others and may be interesting for you:
